Last reviewed · How we verify

NCT04265274

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Withdrawn Phase 2 Last updated 6 October 2023
What this trial tests

Phase 2 trial testing Disulfiram in Metastatic Breast Cancer. Withdrawn.

Timeline
1 January 2020
Primary endpoint
1 January 2022
1 January 2023

Quick facts

Lead sponsorNational Cancer Institute, Slovakia
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 January 2020
Primary completion1 January 2022
Estimated completion1 January 2023
Sites1 location across Slovakia

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Slovakia

Who can join

18 and older, female only, with Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC\_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy.
    Lelièvre P, Sancey L, Coll JL, Deniaud A, et al · · 2020 · cited 197× · PMID 33271772 · DOI 10.3390/cancers12123594
  2. Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.
    Zuhra K, Augsburger F, Majtan T, Szabo C. · · 2020 · cited 157× · PMID 32365821 · DOI 10.3390/biom10050697
  3. Small Molecule NF-κB Pathway Inhibitors in Clinic.
    Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164
  4. Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.
    Babak MV, Ahn D. · · 2021 · cited 125× · PMID 34440056 · DOI 10.3390/biomedicines9080852
  5. The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment.
    Zhang H, Fu L. · · 2021 · cited 116× · PMID 34221859 · DOI 10.1016/j.apsb.2021.02.008
  6. Recent progress in DNA methyltransferase inhibitors as anticancer agents.
    Zhang Z, Wang G, Li Y, Lei D, et al · · 2022 · cited 96× · PMID 37077808 · DOI 10.3389/fphar.2022.1072651
  7. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
    Kannappan V, Ali M, Small B, Rajendran G, et al · · 2021 · cited 94× · PMID 34604310 · DOI 10.3389/fmolb.2021.741316
  8. Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities.
    Huang Z, Zhang Z, Zhou C, Liu L, et al · · 2022 · cited 90× · PMID 35601657 · DOI 10.1002/mco2.144

Verify or expand the search:

Other trials of Disulfiram

Trials testing the same drug.

Other recruiting trials for Metastatic Breast Cancer

Currently open trials in the same condition.

Other National Cancer Institute, Slovakia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04265274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing